Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT PharmaceuticalsSXTC -25.97% Debt-to-EBITDA is 1.83 as of Mar. 2026. The stock has 8 warning signs investors should review. Among 690 Drug Manufacturers companies, China SXT Pharmaceuticals ranks worse than 144927.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for China SXT Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
SXTC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.66 Med: -0.29 Max: 0.22
Current: -0.19
During the past 10 years, the highest Debt-to-EBITDA Ratio of China SXT Pharmaceuticals was 0.22. The lowest was -6.66. And the median was -0.29.
SXTC's Debt-to-EBITDA is ranked worse than 100% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs SXTC: -0.19
China SXT Pharmaceuticals (NAS:SXTC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
China SXT Pharmaceuticals Debt-to-EBITDA Related Terms
China SXT Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SXTC vs CBIH, UPC, NPHC: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
China SXT Pharmaceuticals (SXTC) has a Debt-to-EBITDA of 1.83 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China SXT Pharmaceuticals. According to the industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is China SXT Pharmaceuticals' Debt-to-EBITDA too high?
China SXT Pharmaceuticals' current Debt-to-EBITDA is 1.83. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. China SXT Pharmaceuticals' value of 1.83 is 10.9% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does China SXT Pharmaceuticals' Debt-to-EBITDA compare to CBIH and UPC?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #999999 out of 690 companies for Debt-to-EBITDA. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. China SXT Pharmaceuticals' value of 1.83 is 10.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current Debt-to-EBITDA of 1.83 is 10.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on China SXT Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current Debt-to-EBITDA is 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (SXTC) is currently considered Possible Value Trap. The stock's GF Value™ is $2.05, compared to a current price of $0.05 — trading 97.5% below its estimated fair value. The current Debt-to-EBITDA is 1.83 and 10.9% above the Drug Manufacturers industry median of 1.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For China SXT Pharmaceuticals (SXTC), the current Debt-to-EBITDA is 1.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTC has been successfully added to your 
